“Since its foundation in 1999, the Copenhagen-based company has been developing antibody-based therapies to treat cancer. Now, it is Europe’s perhaps most fiercely independent biotech, though word on the street is that J&J is considering a buyout after the success of Darzalex”, European Biotech editor, Evelyn Warner, from Berlin based, Labiotech.eu, writes, motivating why Genmab belongs on the list.  

Read full Labiotech ranking list here.